← board
ATXI
distress 2/10 · well-funded / low risk$0.27+4%today-71% from 52w high
Lead: spinal bulbar and muscular atrophy (Kennedy's Disease)
Revenue
pre-revenue
Liquidity
$2M
Runway
2.2 yrs
Shares 1y
+4%
Price & events
-35.2% over 6M
CatalystRating changeDilutionFinancingdashed = today
+3.8%
1D
+3.8%
1W
-10.0%
1M
-48.1%
3M
-35.2%
6M
-40.0%
1Y
-92.2%
2Y
-100.0%
5Y
-100.0%
All
Overview
- Market Cap
- $889.64K
- Volume
- 17.00K
- 52 Week Range
- $0.15 – $0.93
- Total Shares
- 3.29M
- Float Shares
- 2.85M
- Short %
- 2.83%
- % Held by Insiders
- 13.51%
- % Held by Institutions
- 7.02%
- RVOL
- 8.73x
- Beta
- -0.17
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 3
- 2026-02-18partnershipATX-04 · Exclusive worldwide license from Duke University for ATX-04 (clenbuterol) to treat Pompe disease.SEC 8-K
- 2025-11-05partnershipBAER-101 (AXS-17) · Axsome purchased 100% equity in Baergic Bio and obtained worldwide rights to BAER-101 (AXS-17).SEC 8-K
- on or before April 15, 2025readoutPhase 1/2AJ201 · Readout of clinical trial for AJ201 assessing efficacy in SBMASEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors — spinal bulbar and muscular atrophy (Kennedy's Disease)
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.